Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer monolconal antibodies - Lanier Biotherapeutics

Next Previous
Drug Profile

Research programme: anti-cancer monolconal antibodies - Lanier Biotherapeutics

Alternative Names: ABM 101; ABM 193; ABM101 - Lanier Biotherapeutics; Anti-OX40 mAb; Anti-PD-L1 mAb; Anti-T-cell antibodies

Latest Information Update: 07 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abeome Corporation
  • Developer Lanier Biotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists; Programmed cell death 1 ligand 2 inhibitors; T-cell receptor antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 05 Oct 2021 Biophtha has merged with Abeome Corporation to form Lanier Biotherapeutics
  • 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 24 Apr 2017 Research programme: anti-cancer monolconal antibodies - Abeome Corporation is available for licensing as of 24 Apr 2017. http://abeomecorp.com (Abeome pipeline, April 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top